Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators.

[1]  C. Hall,et al.  In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. , 1995, Circulation.

[2]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[3]  S. Snapinn,et al.  The plasma concentration of N‐terminal proatrial natriuretic factor anf (1‐98) is related to prognosis in severe heart failure , 1994, Clinical cardiology.

[4]  R. T. Lie,et al.  Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. , 1993, British heart journal.

[5]  G. Lamas,et al.  Activation of neurohumoral systems in postinfarction left ventricular dysfunction. , 1993, Journal of the American College of Cardiology.

[6]  P. Mathisen,et al.  Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. , 1993, Scandinavian journal of clinical and laboratory investigation.

[7]  T. Pindborg,et al.  Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction , 1992, British heart journal.

[8]  D. vesely,et al.  Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distension. , 1991, The American journal of physiology.

[9]  J. López-Novoa,et al.  Atrial natriuretic peptide in patients with acute myocardial infarction without functional heart failure. , 1991, European heart journal.

[10]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[11]  N. Fineberg,et al.  Early recovery of regional left ventricular function after reperfusion in acute myocardial infarction assessed by serial two-dimensional echocardiography. , 1989, The American journal of cardiology.

[12]  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.

[13]  Brumback Ra.  Routine use of phenolized formalin in fixation of autopsy brain tissue to reduce risk of inadvertent transmission of Creutzfeldt-Jakob disease. , 1988 .

[14]  K. Nakao,et al.  γ-Atrial natriuretic polypeptide (γANP)-derived peptides in human plasma: Cosecretion of N-terminal γANP fragment and αANP , 1988 .

[15]  J. Sundsfjord,et al.  Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.

[16]  N. Seidah,et al.  NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: Identification, radioimmunoassay and half-life , 1988, Peptides.

[17]  H. Itoh,et al.  Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP. , 1988, The Journal of clinical endocrinology and metabolism.

[18]  J. Drouin,et al.  Ventricular activation of the atrial natriuretic factor gene in acute myocardial infarction. , 1988, The New England journal of medicine.

[19]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[20]  N. Seidah,et al.  The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. , 1987, The Biochemical journal.

[21]  P. Needleman,et al.  Atriopeptin turnover: quantitative relationship between in vivo changes in plasma levels and atrial content. , 1986, The Journal of pharmacology and experimental therapeutics.

[22]  S. Ball,et al.  Plasma alpha natriuretic peptide in cardiac impairment. , 1986, British medical journal.

[23]  I. Tikkanen,et al.  PLASMA ATRIAL NATRIURETIC PEPTIDE IN CARDIAC DISEASE AND DURING INFUSION IN HEALTHY VOLUNTEERS , 1985, The Lancet.

[24]  J. Dietz.  Release of natriuretic factor from rat heart-lung preparation by atrial distension. , 1984, The American journal of physiology.

[25]  T. Flynn,et al.  The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. , 1983, Biochemical and biophysical research communications.

[26]  J. Forrester,et al.  Comparison of clinical signs and hemodynamic state in the early hours of transmural myocardial infarction. , 1982, American heart journal.

[27]  N Breslow,et al.  Covariance adjustment of relative-risk estimates in matched studies. , 1982, Biometrics.

[28]  I. Cobden,et al.  初期食道静脈りゅう治療におけるテルイプレシン(グリプレシン)とバソプレシンの比較試験 , 1982 .

[29]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[30]  K. Hammermeister,et al.  Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. , 1979, Circulation.

[31]  G. Diamond,et al.  Hemodynamic Spectrum of Myocardial Infarction and Cardiogenic Shock: A Conceptual Model , 1972, Circulation.

[32]  G. Diamond,et al.  Effect of Coronary Artery Disease and Acute Myocardial Infarction on Left Ventricular Compliance in Man , 1972, Circulation.